Skip to main content
Gary Ingenito, MD, Neurology, Scranton, PA

GaryIngenitoMD

Neurology Scranton, PA

Physician

Are you Dr. Ingenito?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 40 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Gary Ingenito, MD is a neurologist in Scranton, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.

Education & Training

  • University of Miami/Jackson Health System
    University of Miami/Jackson Health SystemResidency, Neurology, 1986 - 1989
  • University of Miami/Jackson Health System
    University of Miami/Jackson Health SystemResidency, Neurological Surgery, 1984 - 1986
  • University of Miami/Jackson Health System
    University of Miami/Jackson Health SystemInternship, Transitional Year, 1983 - 1984
  • Sidney Kimmel Medical College at Thomas Jefferson University
    Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1983

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1991 - 2024

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to Be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting
    Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to Be Presented at the Upcoming American Academy of Neurology 2023 Annual MeetingApril 20th, 2023
  • Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies
    Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic EpilepsiesMarch 8th, 2023
  • Catalyst Pharmaceuticals’ Firdapse® (Amifampridine Phosphate) Receives Marketing Approval in Canada for Patients with LEMS
    Catalyst Pharmaceuticals’ Firdapse® (Amifampridine Phosphate) Receives Marketing Approval in Canada for Patients with LEMSAugust 6th, 2020
  • Join now to see all